Institut Curie Paris

Paris 75005

1 studies enrolling now · 6 studies all time

What they study most

Advanced Solid Tumor, Breast Ductal Carcinoma In Situ, HNSCC for Phase 2 Dose Expansion, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Invasive Breast Carcinoma, Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, NSCLC for Phase 2 Dose Expansion, Ovarian Cancer, Recurrent Uveal Melanoma

Studies at this site

• An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors — Recruiting now
• Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma — Running, not enrolling
• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer — Running, not enrolling
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma — Running, not enrolling
• Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Running, not enrolling
• Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors — Completed